| Objective: to probe into the correlation of AR, and PSA during androgen ablation therapy in stage D prostate cancer patients, and find a effective therapy with minimal side effects so as to improve the life quality of the patients and also makes a foundation to treat prostate cancer in clinical use. Methods: We treated prostate cancer patients in stage D with Luteinizing hormone-releasing hormone analog, (LHRH-A) and androgen ablation drug (Flutamide), and combined with the immunohistochemical staining of AR and PSA, and evaluate the effect by the change of serum PSA for two years. We have a statistical analysis among AR and PSA expression, before and after the lever of serum PSA, Gleason score and histo-differentiation by SPSS statistical soft and then to elevate the effect of treatment by the change of serum PSA. Results: The difference among the expression of AR, PSA and histodifferentiation were significantly different. The lever of the serum of PSA during the treatment were significantly different among the tumor grade and there were difference among different Gleason score and the lever of serum of PSA (F=5.396, P =0.010<0.05), and there were difference among the lever of serum of PSA in different times (F=68.200, P =0.000<0.05) and the lever of serum of PSA were significantly difference among different grapes (F=4.883, P =0.005<0.05). The study Among different Gleason score, the lever of serum of PSA and the expression of AR showed that the Gleason score had a positive correlated to the lever of serum of PSA (rs=0.543, P =0.01<0.05) and had a negative correlated to the expression of PSA (rs=-0.800, P =0.0000.05). The lever of serum of PSA hadn'tcorrelated to the expression of PSA. Conclusions: (1) The immunohisto-chemical staining of AR and PSA have a close relation to the effect of androgen ablation therapy in stage D prostate cancer patients. (2)The change of PSA is a valuable marker for watching the recurrent and effective of tumor. |
PDF Full Text Request